- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943949
Effect of a Comprehensive Package Based on Multimarker Blood-based Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory Tract Infections at Village Clinics in China
This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China. We will conduct the trial over six months in 80 village clinics across 10 townships in Xiantao and Jingmen, Hubei Province (with 5 townships in Xiantao and 5 in Jingmen). Village clinics will be randomly assigned in a 1:1 ratio to either the intervention or control group, stratified by city and township. A comprehensive intervention package based on multimarker blood-based POCT will be implemented in 40 village clinics within the intervention group. In addition to equipping these clinics with POCT devices, we will provide systematic guidance through a combination of centralised training sessions and the distribution of training manuals. The training will focus on the standardised operation of POCT and clinical pathways to guide antibiotic prescriptions for the treatment of ARIs based on test results. We will provide patient education through leaflets, primarily aimed at helping rural patients understand how multimarker blood-based POCT can aid in their diagnosis and treatment, thereby improving patient acceptance. The control group will undergo diagnosis and treatment in accordance with routine care procedures, without any intervention.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xiaoxv Yin
- Numéro de téléphone: +86 13871187781
- E-mail: yxx@hust.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Minzhi Xu
- Numéro de téléphone: +86 18737357795
- E-mail: 619581384@qq.com
Lieux d'étude
-
-
Hubei
-
Jingmen, Hubei, Chine, 448000
- 40 Village Clinics
-
Contact:
- Minzhi Xu
- Numéro de téléphone: +86 18737357795
- E-mail: 619581384@qq.com
-
Contact:
- Yifei Chen
- Numéro de téléphone: +86 18186446642
- E-mail: 2026521006@hust.edu.cn
-
Xiantao, Hubei, Chine, 433000
- 40 Village Clinics
-
Contact:
- Minzhi Xu
- Numéro de téléphone: +86 18737357795
- E-mail: 619581384@qq.com
-
Contact:
- Yifei Chen
- Numéro de téléphone: +86 18186446642
- E-mail: 2026521006@hust.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Eligibility criteria for clusters. Village clinics will be eligible if they have not previously participated in a POCT-guided antibiotic prescribing programme, record more than 2,000 outpatient visits annually, manage an average of at least 10 patients with ARIs per week, and have licensed prescribers. Eligibility will be verified using prescription records from the preceding year obtained from the information management departments of the local health authorities.
Eligibility criteria for participants. The target population comprises patients of all ages who either (1) have been diagnosed by village doctors with an ARI, including upper or lower respiratory tract infections; or (2) present with at least one acute respiratory symptom or sign, such as cough, sore throat, rhinitis (nasal congestion, sneezing, or rhinorrhoea), wheezing, or abnormal findings on auscultation. Patients diagnosed with non-respiratory conditions and those whom village doctors consider require referral to a higher-level healthcare facility based on their clinical presentation will be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Control group
The control group will not have any intervention, as the control (usual care) |
|
|
Expérimental: Intervention group
All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs. |
All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs. Each intervention clinic will receive a concise, easy-to-follow decision flowchart summarising the prespecified thresholds for selected CBC parameters, CRP, and SAA. Following randomisation, all village doctors in the intervention group will receive standardised centralised training. The research team will also provide each village clinic in the intervention group with a guidance manual on appropriate antibiotic use for ARIs supported by combined CBC, CRP, and SAA POCT. Plain-language, non-technical information leaflets will be distributed at all village clinics in the intervention group. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The primary outcome will be a binary indicator of whether at least one antibiotic is prescribed by the village doctor during an eligible index consultation for an ARI.
Délai: The 6-month intervention
|
An index consultation is defined as an ARI-related consultation by a patient who has not had any recorded ARI consultations at the same village clinic in the preceding 14 days. This measure aims to capture the overall effect of the POCT-supported multicomponent intervention on antibiotic prescribing decisions for ARIs. Since most ARIs are viral and self-limiting, a lower prescribing proportion-provided that patient recovery and safety are not compromised-would indicate more selective use of antibiotics by village doctors. This endpoint is particularly suitable for research in village clinics in China because prescriptions are now routinely recorded electronically rather than solely on paper. These digital records enable standardised data extraction and auditing, thereby supporting the completeness and traceability of outcome ascertainment. |
The 6-month intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
The proportion of eligible index consultations in which two or more antibiotics are prescribed
Délai: The 6-month intervention
|
The 6-month intervention
|
|
The proportion in which at least one antibiotic is administered intravenously
Délai: The 6-month intervention
|
The 6-month intervention
|
|
The proportion in which at least one traditional Chinese medicine is prescribed
Délai: The 6-month intervention
|
The 6-month intervention
|
|
The medication cost per eligible index consultation
Délai: The 6-month intervention
|
The 6-month intervention
|
|
The total cost per eligible index consultation
Délai: The 6-month intervention
|
The 6-month intervention
|
Autres mesures de résultats
Mesure des résultats |
Délai |
|---|---|
|
The proportion of patients who initiate any additional antibiotic during the 14 days following an eligible index consultation for an ARI will be assessed in a randomly selected subsample
Délai: The 6-month intervention
|
The 6-month intervention
|
|
The principal safety outcome will be the proportion of patients admitted to any hospital within the corresponding study city for an ARI or sepsis within 30 days after the index consultation.
Délai: The 6-month intervention
|
The 6-month intervention
|
|
In the randomly selected patient subsample, we will also assess time to recovery from ARI symptoms through the 14-day telephone follow-up.
Délai: From the index consultation to the end of treatment at 2 weeks
|
From the index consultation to the end of treatment at 2 weeks
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- HuazhongU20261111
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .